Is ILMN a Buy? What to Consider in 2026
Short answer
The bull case for Illumina (ILMN) rests on Installed base and the consumables annuity: Illumina's core advantage is the large base of sequencers already in labs, which pulls through recurring reagent and flow-cell purchases. Revenue (FY2025) is ~$4.34 billion (approximate, verify). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. Whether ILMN is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. Its business follows a razor-and-blades model: instruments such as the high-throughput NovaSeq X, the NextSeq, and the benchtop MiSeq seed an installed base, and the bulk of revenue then comes from recurring sequencing consumables (reagents and flow cells), which historically make up the majority of sales. The company is also pushing into multiomics, proteomics, and clinical diagnostics to expand what its platforms can measure. Illumina is headquartered in San Diego, was founded in 1998, and is led by CEO Jacob Thaysen. Illumina's recent history was dominated by its acquisition of cancer-screening company GRAIL and the regulatory fight that followed. Antitrust authorities in the US and Europe challenged the deal, the European Commission ordered a divestiture in 2023, and Illumina distributed about 85.5% of GRAIL to its shareholders in June 2024, separating the two companies. In September 2024 the European Court of Justice annulled the Commission's jurisdiction over the original review, and Illumina avoided a 432 million euro fine. With GRAIL gone, management has refocused the company on its core sequencing platforms, consumables growth, multiomics, and operating-margin recovery.
What's the case for buying ILMN?
1. Installed base and the consumables annuity.
Illumina's core advantage is the large base of sequencers already in labs, which pulls through recurring reagent and flow-cell purchases. Sequencing consumables revenue was about $755 million in the fourth quarter of 2025, up 8% year over year and roughly 11% excluding China. As long as customers keep running these machines, consumables provide a relatively sticky, high-visibility revenue stream.
2. The NovaSeq X transition.
The high-throughput NovaSeq X drives lower cost per genome and higher consumables volume as it replaces older systems. Illumina reported the installed base reaching roughly 890 instruments by the end of 2025, with the research transition nearly complete and clinical conversion past two-thirds. Each placement seeds future consumables demand, so the pace of conversion matters to the growth story.
3. Multiomics and clinical diagnostics.
Beyond DNA sequencing, Illumina is expanding into proteomics, single-cell, and spatial methods, and is leaning into clinical applications such as comprehensive genomic profiling in oncology and whole-genome sequencing in genetic disease. Clinical consumables excluding China grew about 20% in the fourth quarter of 2025, a faster-growing mix the company is trying to enlarge.
4. Margin recovery.
After the GRAIL distraction and a cost-reduction program, Illumina is targeting improved profitability. For fiscal 2026 it guided to a non-GAAP operating margin in roughly the 23.3% to 23.5% range, with operating margin around 22% reported in the first quarter of 2026. Continued margin expansion is a key part of how the company frames its earnings recovery.
What are the risks to ILMN?
Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. The underlying sequencing market is growing slowly, and soft academic and research funding, including pressure on US research budgets, can delay instrument purchases. China is now only about 3% of revenue after Illumina was effectively shut out of that market, where domestic players BGI and MGI dominate. Tariffs and a relatively high valuation add further risk.
How is ILMN valued? (as of June 2026)
- Revenue (FY2025): ~$4.34 billion (approximate, verify)
- 2026 revenue guidance: ~$4.5-4.6 billion, ~4-6% growth (company guidance, verify)
- Consumables mix: Majority of revenue is recurring consumables (razor-and-blades; verify)
- Non-GAAP operating margin (2026 guide): ~23.3-23.5% (company guidance, verify)
- P/E (TTM): ~32x (approximate, moves with price; verify)
- Market cap: ~$26-27 billion (approximate, verify)
Illumina trades at a premium earnings multiple that reflects its platform dominance and consumables annuity, set against low-single-digit revenue growth and a slow-growing end market. Full-year 2025 revenue was about $4.34 billion, and the company guided fiscal 2026 to roughly $4.5 to $4.6 billion with operating margins recovering toward the low-to-mid 20s. All figures are approximate, tied to the June 2026 asOf date, and move with the share price and reported results; verify current numbers before relying on them.
How do you decide if ILMN is a buy?
Rather than asking whether ILMN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ILMN indirectly through an index or sector ETF before adding more.
For the full picture, see the ILMN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ILMN against your real portfolio and see your actual exposure before deciding.
The bottom line on ILMN
The bottom line: Illumina's story right now is Installed base and the consumables annuity, with revenue (fy2025) at ~$4.34 billion (approximate, verify). If you believe that narrative continues, the call is about sizing ILMN sensibly and checking overlap with what you own; if you doubt it (the risk: competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ILMN with Walnut
Use Illumina as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ILMN a good stock to buy right now?
+
The case for Illumina right now is Installed base and the consumables annuity, with revenue (fy2025) at ~$4.34 billion (approximate, verify). If you believe that thesis holds, ILMN is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Illumina do?
+
Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers.
What are the main risks of ILMN?
+
Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. The underlying sequencing market is growing slowly, and soft academic and research funding, including pressure on US research budgets, can delay instrument purchases. China is now only about 3% of revenue after Illumina was effectively shut out of that market, where domestic players BGI and MGI dominate. Tariffs and a relatively high valuation add further risk.
What does Illumina do?
+
Illumina makes next-generation DNA sequencing systems and the consumables that run on them, used in genomics research, clinical diagnostics, and applied markets. It follows a razor-and-blades model: instruments such as the NovaSeq X, NextSeq, and MiSeq seed an installed base, and most revenue comes from recurring reagents and flow cells. The company is also expanding into multiomics.
What is Illumina's (ILMN) ticker symbol?
+
ILMN, listed on Nasdaq. Officially Illumina, Inc., headquartered in San Diego, California, and founded in 1998. It is a constituent of the S&P 500 and Nasdaq-100 and trades during US market hours at every major US brokerage, where you can buy whole or fractional shares.
What happened with Illumina and GRAIL?
+
Illumina acquired cancer-screening company GRAIL, but antitrust regulators in the US and Europe challenged the deal. The European Commission ordered a divestiture, and Illumina distributed about 85.5% of GRAIL to shareholders in June 2024. In September 2024 the European Court of Justice annulled the Commission's jurisdiction, and Illumina avoided a 432 million euro fine.
Does Illumina (ILMN) pay a dividend?
+
No. As of June 2026 Illumina does not pay a dividend. The company directs cash toward research and development, its platform transition, and operations rather than a regular payout, so total return depends on the share price. Dividend policy can change, so verify the current status before relying on it.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ILMN; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.